AMP Stakeholder Dinner To Celebrate Next Frontier of HIV Research

By | Events, Fenway Health Newsroom, Fenway News, HIV/AIDS | No Comments
You’ve heard about PrEP, the daily pill that is proven to drastically reduce one’s chances of contracting HIV. The Fenway Institute is excited to be part of the AMP (Antibody Mediated Prevention) Study, a groundbreaking study that has the potential to radically change the way we fight HIV. On May 4 at 6 PM, LGBTQ community leaders, researchers, and HIV advocates will gather at Boston’s Club Café for A New Frontier: Looking Beyond PrEP Toward Antibody Mediated Prevention. We invite you to join us at this stakeholder dinner as we discuss the next historic step towards ending this epidemic in 
Read More

Preventing HIV with One Pill a Day: Using PrEP in Clinical Practice

By | Education, Events, Fenway Health Newsroom, Fenway News, HIV/AIDS, The Fenway Institute | No Comments
The Fenway Institute and the National LGBT Health Education Center are excited to announce an upcoming educational conference for medical providers about the usage of on PrEP (pre-exposure prophylaxis) for HIV prevention. PrEP, also known by the brand name Truvada, is a once-daily HIV prevention pill with the potential to make a significant contribution to ending the HIV/AIDS epidemic. You are invited to attend a continuing education conference focused on teaching providers how to incorporate PrEP into their clinical practice. The conference is for any providers – including primary care or other relevant providers – who are interested in becoming 
Read More

Vacation Study Examines Efficacy of Short-Term PrEP Use

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute | No Comments
As the weather grows colder, many people are starting to plan their 2016 vacations. Among the TSA screenings and hotel ratings, there is one rarely discussed aspect of travel planning and safety: sexual health. Research has shown that many men who have sex with men (MSM) have periods of elevated HIV risk that often coincide with times away from home or vacations. The often casual and spontaneous nature of sexual encounters while traveling can result in unprotected sex and, in doing so, raise one’s risk of HIV infection. Pre-exposure prophylaxis (PrEP), a daily pill to prevent HIV infection, is a 
Read More

Issue Brief Addresses Transgender Women, PrEP Research, and Hormone Concerns

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, LGBT Health, The Fenway Institute, Trans | One Comment
A policy brief released today by the National Center for Innovation in HIV Care—a program of The Fenway Institute, AIDS United, and ARCW—examines questions that have been raised about the interaction between feminizing hormones used by transgender women, and the medication currently approved for use as pre-exposure prophylaxis for HIV prevention (PrEP). It calls on the scientific community to conduct more research on PrEP with transgender women, and urges transgender women who are HIV-negative to discuss PrEP with their doctors as a potential option for helping them stay HIV-negative. Transgender women are 49 times more likely to have HIV than 
Read More

New Campaign Highlights Benefits Of Daily PrEP Use

By | AIDS Action Committee, Fenway Health Newsroom, HIV Prevention, HIV/AIDS | No Comments
The AIDS Action Committee is pleased to announce the launch of a new advertising campaign that aims to educate the public on the benefits of pre-exposure prophylaxis (PrEP) in the fight against HIV. Also commonly known by the brand name Truvada, PrEP is a daily pill that, when taken daily, has proven to be 99% effective in preventing HIV infection. The Talk PrEP campaign hopes to raise public awareness of PrEP’s efficacy and encourage people to start conversations with their friends, family, and doctors about this life-saving drug. Anyone who is HIV-negative, does not have degenerative kidney or liver disease 
Read More